These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
25. [Radioactive substances (32P and 89Sr) in the treatment of pain in bone metastases]. Flamm J; Burkert S Z Urol Nephrol; 1981 Nov; 74(11):801-6. PubMed ID: 6172913 [TBL] [Abstract][Full Text] [Related]
26. Decreased serum E-selectin concentration after 89Sr-chloride therapy for metastatic prostate cancer bone pain. Papatheofanis FJ J Nucl Med; 2000 Jun; 41(6):1021-4. PubMed ID: 10855628 [TBL] [Abstract][Full Text] [Related]
27. Strontium-89 for treatment of painful bone metastasis from prostate cancer. Altman GB; Lee CA Oncol Nurs Forum; 1996 Apr; 23(3):523-7. PubMed ID: 8801513 [TBL] [Abstract][Full Text] [Related]
28. [Strontium chloride (89Sr-chloride) fractional injection method for bone metastases treatment]. Fomin DK; Smirnov IuN; Tararukhina OB; Nazarov AA Vopr Onkol; 2012; 58(1):116-8. PubMed ID: 22629840 [TBL] [Abstract][Full Text] [Related]
29. [Preliminary application of strontium-89 for the treatment of bone metastases from prostate cancer]. Zhao W; Deng H; Jie P; Qing C; Zhang X Sheng Wu Yi Xue Gong Cheng Xue Za Zhi; 2010 Dec; 27(6):1251-4. PubMed ID: 21374974 [TBL] [Abstract][Full Text] [Related]
30. Quantitation of biochemical markers of bone resorption following strontium-89-chloride therapy for metastatic prostatic carcinoma. Papatheofanis FJ J Nucl Med; 1997 Aug; 38(8):1175-9. PubMed ID: 9255144 [TBL] [Abstract][Full Text] [Related]
31. [Influence of 89Sr on the cell immune function in patients with multiple bone metastases]. Wu YG; Ma QL; Liu GF Hunan Yi Ke Da Xue Xue Bao; 2002 Jun; 27(3):277-8. PubMed ID: 12575316 [TBL] [Abstract][Full Text] [Related]
32. [Treatment of symptomatic bone metastases of prostatic carcinoma using strontium chloride (Sr-89)]. Dormia E; Mantovani F; Minervini S; Malagola G; Castellani R; Dormia G; Gonnella G; Mazza L; Luongo P; Bertana F Arch Ital Urol Androl; 1993 Apr; 65(2):161-6. PubMed ID: 8330061 [TBL] [Abstract][Full Text] [Related]
33. [Imaging of strontium-89 uptake with bremsstrahlung using NaI scintillation camera]. Narita H; Uchiyama M; Ooshita T; Hirase K; Makino M; Mori Y; Sekine H; Kawakami K Kaku Igaku; 1996 Nov; 33(11):1207-12. PubMed ID: 8986059 [TBL] [Abstract][Full Text] [Related]
34. [2 years of experience with 89Sr therapy of multiple bone metastases (author's transl)]. Correns HJ; Mitterlechner E; Buchali K; Schnorr D; Seidel C; Mebel M Radiobiol Radiother (Berl); 1979 Jun; 20(3):360-2. PubMed ID: 515396 [No Abstract] [Full Text] [Related]
35. [Strontium-89: a desirable therapeutic for bone metastases of prostate cancer]. Ma YB; Yan WL; Dai JC; Xu F; Yuan Q; Shi HH Zhonghua Nan Ke Xue; 2008 Sep; 14(9):819-22. PubMed ID: 18998467 [TBL] [Abstract][Full Text] [Related]
36. Disseminated intravascular coagulation in a patient treated with strontium-89 for metastatic carcinoma of the prostate. Paszkowski AL; Hewitt DJ; Taylor A Clin Nucl Med; 1999 Nov; 24(11):852-4. PubMed ID: 10551466 [TBL] [Abstract][Full Text] [Related]
37. A model-based method for the prediction of whole-body absorbed dose and bone marrow toxicity for 186Re-HEDP treatment of skeletal metastases from prostate cancer. Buffa FM; Flux GD; Guy MJ; O'Sullivan JM; McCready VR; Chittenden SJ; Dearnaley DP Eur J Nucl Med Mol Imaging; 2003 Aug; 30(8):1114-24. PubMed ID: 12761596 [TBL] [Abstract][Full Text] [Related]